FindTrial
Sign In

Vulvovaginal Candidiasis- Spot diagnosis and Novel treatment modality

Development Of a Novel Point-Of-Care- Testing Device For Rapid Diagnosis And Evaluation Of In-Vitro Therapeutic Potential Of IgY antibody For Vulvovginal Candidiasis At a Tertiary Care Hospital. - NIL

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/10/074942
Enrollment
100
Registered
2024-10-08
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N898- Other specified noninflammatory disorders of vagina

Interventions

Intervention1: nil: nil

Sponsors

Deeksha p
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: The study includes Candida isolates from vaginal swabs of sexually active women aged above 18 years from Obstetrics and Gynaecology that are routinely sent to the Microbiology laboratory.

Exclusion criteria

Exclusion criteria: Age less than 18 years. Patients on any antifungal therapy 6 weeks prior to sample collection were excluded from the study Patients other than Candida infection

Design outcomes

Primary

MeasureTime frame
Novel point of care testing device based on the principle of lateral flow immunoassay and colorimetric method to diagnose vulvovaginal candidiasis rapidly and accurately will be developed Timepoint: October 2024- March 2026—

Secondary

MeasureTime frame
Therapeutic potential of IgY antibodies to inhibit biofilm formation OF DRUG RESISTANT Candida species in-vitro will be identified Timepoint: January 2025-March 2026—

Countries

India

Contacts

Public ContactDr Sajeetha KumariR

SRM Medical college Hospital and Research Centre

sajeethaprabhakar@gmail.com9940170195

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026